Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 4/20 | 0.60 |
| ▸ | THRB | P10828 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | BCHE | P06276 | 4/20 | 0.52 |
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14287619 | 0.83 | THRA (0.74) | THRATHRBALDH1A1KDM4EBCHE | |
| SCHEMBL26054446 | 0.79 | ALDH1A1 (0.58) | THRATHRBALDH1A1KDM4EBCHE | |
| SCHEMBL6057567 | 0.78 | ALDH1A1 (0.63) | THRATHRBALDH1A1KDM4EBCHE | |
| SCHEMBL3279580 | 0.77 | ALDH1A1 (0.51) | ALDH1A1KDM4EL3MBTL1SMN1; SMN2MAPT | |
| SCHEMBL14287626 | 0.76 | L3MBTL1 (0.73) | THRATHRBALDH1A1KDM4EBCHE | |
| SCHEMBL4966805 | 0.76 | TP53 (0.63) | ALDH1A1KDM4EBCHEACHESMN1; SMN2 | |
| SCHEMBL864407 | 0.76 | THRA (0.72) | THRATHRBALDH1A1BCHEACHE | |
| SCHEMBL4968205 | 0.75 | ALDH1A1 (0.60) | THRATHRBALDH1A1KDM4EBCHE | |
| SCHEMBL6630485 | 0.75 | ALDH1A1 (0.60) | THRATHRBALDH1A1KDM4EBCHE | |
| SCHEMBL19659861 | 0.75 | THRA (0.80) | THRATHRBL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261975-A1 | Tec Kinase Inhibitors | BENTZIEN JOERG MARTIN | 2008-10-23 | — | — | US | disclosed |
| EP-1957491-A2 | PYRROLO (2,3-B) PYRIDINE DERIVATIVES USEFUL AS TEC KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007058832-A2 | PYRROLO (2, 3-B) PYRIDINE DERIVATIVES USEFUL AS TEC KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261975-A1 | Tec Kinase Inhibitors | TEC, ITK, LCK | THRA 1682/4885THRB 1468/4885ALDH1A1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.